Dr. Ariel Katz, CEO of Vaya Pharma, presented to executives from Children’s Healthcare of Atlanta at a meeting they hosted for AICC’s Medical Committee last month. With its US subsidiary in Greenville, South Carolina, the company is a research-based, specialty pharmaceutical division of Migdal Ha’emek-based Enzymotec dedicated to the discovery, development, manufacture and marketing of innovative, clinically tested, effective and safe natural lipids-based medicines. It was set up in Greenville to market their pharmaceutical products that treat ADHD, high cholesterol, and early stage memory loss. Vaya Pharma is already selling in several states including Virginia, Georgia, South Carolina, and North Carolina. Another 15 products are already in the pipeline. The company has recently hired two sales employees in Atlanta to help expand their reach in the region.
Their products meet cGMP standards, and are intended to be used under the supervision of a physician. Vaya’s approach follows the Orthomolecular Medicine concept which describes the practice of preventing and treating disease by providing optimal amounts of substances which are familiar to the body as opposed to synthetic drugs which are foreign to the human body. As Orthomolecular Medicine is based on substances that are normally present in the human body, they are considered to be very safe medicines. Their approach is to use proprietary, clinically tested nutrients to treat specific illness or disorders.
Katz told the Medical Committee that the company is very happy with their decision to locate this second US subsidiary in Greenville (first one is in New Jersey), and asked the group to help Vaya Pharma in introductions to the medical community, members who are knowledgeable with reimbursement and regulatory issues, and researchers. For more information, contact Guy Tessler (email@example.com).